These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 9724095)
1. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Ye Y; Vasavada S; Kuzmin I; Stackhouse T; Zbar B; Williams BR Int J Cancer; 1998 Sep; 78(1):62-9. PubMed ID: 9724095 [TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
3. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Corless CL; Kibel AS; Iliopoulos O; Kaelin WG Hum Pathol; 1997 Apr; 28(4):459-64. PubMed ID: 9104946 [TBL] [Abstract][Full Text] [Related]
4. Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression. Schraml P; Hergovich A; Hatz F; Amin MB; Lim SD; Krek W; Mihatsch MJ; Moch H Am J Pathol; 2003 Sep; 163(3):1013-20. PubMed ID: 12937142 [TBL] [Abstract][Full Text] [Related]
5. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613 [TBL] [Abstract][Full Text] [Related]
6. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. Pioli PA; Rigby WF J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223 [TBL] [Abstract][Full Text] [Related]
7. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493 [TBL] [Abstract][Full Text] [Related]
8. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918 [TBL] [Abstract][Full Text] [Related]
9. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Koochekpour S; Jeffers M; Wang PH; Gong C; Taylor GA; Roessler LM; Stearman R; Vasselli JR; Stetler-Stevenson WG; Kaelin WG; Linehan WM; Klausner RD; Gnarra JR; Vande Woude GF Mol Cell Biol; 1999 Sep; 19(9):5902-12. PubMed ID: 10454537 [TBL] [Abstract][Full Text] [Related]
10. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Tsuchiya H; Iseda T; Hino O Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032 [TBL] [Abstract][Full Text] [Related]
11. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164 [TBL] [Abstract][Full Text] [Related]
12. The von Hippel-Lindau tumour suppressor protein: new perspectives. Ohh M; Kaelin WG Mol Med Today; 1999 Jun; 5(6):257-63. PubMed ID: 10366821 [TBL] [Abstract][Full Text] [Related]
13. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597 [TBL] [Abstract][Full Text] [Related]
14. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor. Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534 [TBL] [Abstract][Full Text] [Related]
15. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Lee S; Neumann M; Stearman R; Stauber R; Pause A; Pavlakis GN; Klausner RD Mol Cell Biol; 1999 Feb; 19(2):1486-97. PubMed ID: 9891082 [TBL] [Abstract][Full Text] [Related]
16. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130 [TBL] [Abstract][Full Text] [Related]
17. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071 [TBL] [Abstract][Full Text] [Related]
18. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612 [TBL] [Abstract][Full Text] [Related]
19. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway. Qi H; Ohh M Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498 [TBL] [Abstract][Full Text] [Related]
20. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Sufan RI; Jewett MA; Ohh M Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]